The drug was approved by the FDA in 2022 as the first medicine to treat hemolytic ... The CLDN18.2 biomarker is expressed by about 35% of Chinese stomach cancer patients, according to Astellas.
It was Valentine's Day when my world turned upside down. I was on a half-term break in Suffolk with my children. We were pottering around with my parents when my phone rang.